Webcast

Informed Therapy for Black Women with Triple-Negative Breast Cancer: Meeting Them Where They Are and Moving Toward Better Outcomes

Launch Date
06/10/2022
Credit Amount
1.0 Hours
Credit Expires
06/10/2023

Faculty

Sara A. Hurvitz, MD, FACP
Professor, Division of Hematology-Oncology
Department of Medicine, David Geffen School of Medicine at UCLA
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Director, Breast Oncology Program, Division of Hematology-Oncology
University of California, Los Angeles
Los Angeles, CA
Sara A. Hurvitz, MD, FACP

Sara A. Hurvitz, MD, is a Professor of Medicine at the University of California, Los Angeles (UCLA), Co-Director of the Santa Monica-UCLA Outpatient Oncology Practice, Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA, and Director of Breast Oncology. Dr. Hurvitz earned her MD from the University of Southern California. She served her internship and residency at UCLA, was Chief Resident of internal medicine, and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz is board certified in internal medicine, hematology, and medical oncology.

Dr. Hurvitz has received numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award from 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing, and leading multiple national and international clinical trials testing new targeted therapies, and leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.

Rita Nanda, MD
Associate Professor of Medicine and Director, Breast Oncology, University of Chicago, Chicago, IL
Rita Nanda, MD

Rita Nanda, MD, is an Associate Professor of Medicine and Director of Breast Oncology at the University of Chicago. Dr. Nanda earned her undergraduate degree in Chemical Engineering from the Massachusetts Institute of Technology, and her Medical Degree from the University of Chicago, Pritzker School of Medicine. She subsequently completed her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at the University of Chicago.

Dr. Nanda’s research interests include identifying novel treatments for the management of breast cancer, particularly triple-negative disease. Dr. Nanda has authored numerous scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer.

She is a member of the Breast Immuno-Oncology (BIO) Taskforce of the National Cancer Institute (NCI) Breast Cancer Steering Committee (BCSC) and serves as a Principal Investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the ISPY2 Clinical Trial Network. She is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the Society for Immunotherapy of Cancer.

Dr. Nanda’s research has been funded by the NIH, the Department of Defense Breast Cancer Research Program, the Doris Duke Charitable Foundation, the Susan G. Komen Foundation, the Metastatic Breast Cancer Network, and the Breast Cancer Research Foundation. She was awarded the 2014 NCI Cancer Clinical Investigator Team Leadership Award, and currently serves as the co-PI for the University of Chicago Interdisciplinary Cancer Health Disparities SPORE.

Kristen Whitaker, MD, MS
Assistant Professor, Department of Medicine (Medical Oncology), Georgetown Lombardi Comprehensive Cancer Center, Washington Hospital Center, Washington, DC.
Kristen Whitaker, MD, MS

Dr. Whitaker is an Assistant Professor in the Department of Medicine (Medical Oncology) at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. Dr. Whitaker’s practice focused on patients with breast cancer and patients at high risk for breast and ovarian cancer. Her research interests include cancer health disparities, cancer screening for high-risk women, hereditary breast cancer, and improved clinical trial enrollment of minority patients with cancer.

She received her undergraduate degree at the University of Pennsylvania and MD from Drexel University College of Medicine.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credits

Statement of Need

Black women are disparately affected by triple-negative breast cancer (TNBC), experiencing higher mortality rates and poorer outcomes than White women, often due to screening delays leading to later-stage diagnoses. Lifting the barriers to access begins with addressing the social determinants of health and distrust of the health care system that prevent many Black women from seeking care. Outcomes improve when health care professionals (HCPs) understand these inequities and include Black women’s perspectives in treatment decisions. When HCPs integrate patient perspectives and preferences and use guideline-driven protocols, they lessen the inequities between Black and White women with TNBC. Engaging Black women throughout the process, from earlier screening to shared treatment decision-making to inclusion in clinical trials, HCPs can meet Black women where they are and move toward better outcomes.

In this CMEO Webcast, expert faculty will discuss the health inequities Black women with TNBC face, in screening, treatment, and outcomes, and how these disparities relate to the social determinants of health. In addition, they will present treatment protocols and guidelines, including the latest agents approved to treat TNBC, to help reduce these inequities. Lastly, faculty will outline how understanding the obstacles and barriers that Black women face can help inform better treatments and outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Evaluate the changing landscape of treatment options for high-risk TNBC to inform therapy plans.
  • Recognize the disparate impact of TNBC in Black Women.
  • Engage to empower Black women regarding mammography screenings, treatment decisions, and participation in clinical trials.

Financial Support

Supported by an educational grant from Merck Sharpe & Dohme Corp.

Target Audience

Physicians, PAs, nurse practitioners, nurses, pharmacists and clinical researchers specializing in oncology.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.0 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

California Residents

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit. Jump to Activity UAN.
Activity UAN: JA0007185-0000-21-070-H01-P

PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Hurvitz reports the following financial relationships: Consultant/Advisory Board (Uncompensated): 4DPharma plc; Ambrx; Amgen Inc.; Artios Pharma; Arvinas; Biotheranostics; Daiichi Sankyo, Inc.; Dantari; Eli Lilly and Company; Genentech, Inc./Roche; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; NKMAX Co., Ltd.; Pieris Pharmceuticals, Inc.; Pyxis Oncology; and Seagen Inc. Grants (Paid to UCLA): Ambrx and Samumed, LLC. National/International Principal Investigator: Daiichi Sankyo, Inc.; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; and Seagen Inc. Research Support (Paid to Institution): Ambrx; Amgen Inc.; AstraZeneca; Arvinas; Bayer AG; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dignitana; Eli Lilly and Company; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Orinove Inc.; Pfizer Inc.; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc. Steering Committee: Lilly; Daiichi Sankyo, Inc./AstraZeneca; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; and Sanofi

Dr Nanda reports the following financial relationships: Advisory Board: AstraZeneca; BeyondSpring Inc.; Cardinal Health; Fujifilm; Immunomedics/Gilead Sciences, Inc.; Infinity. Pharmaceuticals, Inc.; iTeos Therapeutics; MacroGenics, Inc.; Merck & Co., Inc.; OBI Pharma; OncoSec Medical Incorporated; and Seagen Inc. Research Support: Arvinas; AstraZeneca; Celgene Corporation; Corcept Therapeutics; Genentech, Inc./Roche; Immunomedics; Merck & Co., Inc.; OBI Pharma; Odonate Therapeutics, Inc.; OncoSec Medical Incorporated; Pfizer Inc.; Seattle Genetics, Inc.; and Taiho. Oncology, Inc.

Dr. Whitaker reports the following financial relationships: Consultant: Novartis. Grants: The V Foundation for Cancer Research. Research Support: The V Foundation for Cancer Research and National Institutes of Health (NIH). Other Financial or Material Support: Axis Medical Education and Total Health Conferencing

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • David Modrak, PhD (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Thomas Mitchell (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-070-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WCV-048-061022-44

Related Activities

Diversity & Inclusion
09/19/2022

Real-world Tactics to Address Health Inequities in Lung Cancer Care

1.00 Hours
Begin Learn More
Dermatology
09/13/2022

Real-world Tactics to Address Health Inequities in Melanoma Care

0.50 Hours
Begin Learn More
Oncology
07/11/2022

Root Cause Analysis: Examining Structural Racism and SDoH to Combat Inequities in Cancer Care

0.75 Hours
Begin Learn More
Informed Therapy for Black Women with Triple-Negative Breast Cancer: Meeting Them Where They Are and Moving Toward Better Outcomes
Event Date: 06/10/2022
Begin